STATEMENT OF NEED
Multiple myeloma (MM) is a B-cell neoplasm characterized by aberrant expansion of plasma cells within the bone marrow and extramedullary sites (eg, cortical bone). Approximately 32,270 new cases of MM are diagnosed in the United States annually and 12,830 people die of the disease. Although the tumor cells remain primarily within the bone marrow, they can cause a number of complications, including localized bone destruction, anemia, decreased immunity to infection, and kidney damage. MM is primarily considered a disease of older adults, with a median age at diagnosis of 69 years. From 1975 to 2007, the incidence increased by 11.4%, and is expected to continue to rise in conjunction with the aging population. Early diagnosis is difficult because symptoms often do not appear until the malignancy is in advanced stages. The 5-year survival rate remains only 52.2%.
Oncology nurses, nurse practitioners, clinical nurse specialists, and other health care professionals involved in the treatment of patients with MM.
Upon completion of this activity, participants should be able to:
Learning objectives apply to all professions in the target audience. There are no prerequisites for this activity.
Beth Faiman, PhD, MSN, APN-BC, AOCN® (Chairperson)
Nurse Practitioner, Department of Hematologic Oncology
Cleveland Clinic Taussig Cancer Institute
There is no fee to participate in or claim NCPD credit for this activity.
Please note that USF Health and i3 Health do not accept responsibility for travel, accommodation, or any other costs incurred by registrants in the rare event that this activity should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation.
Jointly Provided by
Continuing Nursing Education
USF Health is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 1.0 contact hour may be earned by learners who successfully complete this nursing continuing professional development activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS WITH COMMERCIAL INTERESTS
USF Health and i3 Health endorse the standards of the ANCC that require everyone in a position to control the content of an NCPD activity to disclose all financial relationships with commercial interests that are related to the content of the NCPD activity. NCPD activities must be balanced, independent of commercial bias and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when individuals in a position to control the content of NCPD have a relevant financial relationship with a commercial interest which, therefore, may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.
USF Health will identify, review and resolve all conflicts of interest that speakers, authors or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. USF Health does not endorse any products or services.
Planning Committee, USF Health OCPD staff members, i3 Health staff members, and the peer/content reviewer for this activity have no relevant financial relationships to disclose.
Disclosures are on file at the University of South Florida, Office of Continuing Professional Development. Detailed disclosures will be made in the activity syllabus.
Relevant financial relationships exist between the following individuals and commercial interests:
Beth Faiman, PhD, MSN, APN-BC, AOCN® discloses that she has served on the advisory board/panel for Bristol Myers Squibb, Celgene Corporation, and Takeda. She has also served as a consultant for Bristol Myers Squibb and Celgene Corporation.
REQUIREMENTS FOR CREDIT
Participants must sign-in before the start of the activity to verify attendance. All participants are asked to complete a pretest and a posttest for outcomes assessment; a passing score is not required. At the conclusion of the activity participants must complete an evaluation, attesting to the time spent in this live activity, claiming credit. Certificates of Completion will be emailed to within two weeks of the activity.
UNAPPROVED USE DISCLOSURE
USF Health and i3 Health require NCPD faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
The information provided at this NCPD activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
This activity is supported by independent educational grants from Celgene Corporation, Sanofi Genzyme, and Karyopharm Therapeutics. Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
AMERICANS WITH DISABILITIES ACT